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Abstract 
Large volume leukapheresis: Efficacy and safety of processing patient's total blood 
volume six times 
 
Large-volume leukapheresis (LVL) differs from standard leukapheresis by increased 
blood flow and altered anticoagulation regimen. An open issue is to what degree a further 
increase in processed blood volume is reasonable in terms of higher yields and safety. In 
30 LVL performed in patients with haematologic malignancies, 6 total blood volumes 
were processed. LVL resulted in a higher CD34+ cell yield, without change in graft 
quality. Although a marked platelet decrease can be expected, LVL is safe and can be 
recommended as the standard procedure for patients who mobilize low numbers of 
CD34+ cells and when high number of CD34+ cells are required. 
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1. Introduction  
 Peripheral blood has become widely accepted source of hematopoietic stem cells 
because of easier accessibility and faster engraftment [1]. Since rapid and sustained 
engraftment following high-dose therapy depends on the numbers of stem cells reinfused, 
efforts are directed towards harvesting sufficient numbers of CD34+ cells. Quality of the 
peripheral blood stem cell (PBSC) graft is affected by the effectiveness of mobilization of 
stem cells, proper timing of collection, and the efficiency of collection technique [2]. 
Although sufficient PBSCs may be obtained in a single leukapheresis, the majority of 
patients require repeated procedures. An alternative to repeated aphereses could be 
processing larger volumes of blood during one procedure. Large-volume leukapheresis 
(LVL) involves processing patient's total blood volume (TBV) at least three times during 
single procedure, and differs from standard leukapheresis by processing larger blood 
volume, increasing blood flow rate, use of additional anticoagulant heparin and longer 
duration of procedure [1-5]. Unfortunately, there is no standardized protocol for LVL and 
between centers there are differences regarding blood volume processed and duration of 
procedure. An open issue is to what degree a further increase in processed blood volume 
is reasonable in terms of higher cell yields and safety. 
 The purpose of this study was to investigate efficiency and safety of processing 6 
TBVs. We prospectively analyzed the kinetics of peripheral blood cells and CD34+ cell 
yield during LVL, and intraapheresis recruitment of CD34+ cells. Finally, we evaluated 
whether the prolonged procedure and processing 6 instead of 4 TBVs altered the quality 
of leukapheresis product. 
 
Bojanic,  4 
 
2. Patients and methods 
2.1. Patients 
 Study was performed on group of 30 patients treated at University Hospital 
Centre Zagreb (table 1.). All patients were candidates for high-dose chemotherapy 
followed by autologous PBSC transplantation. PBSCs were mobilized by combination of 
disease specific chemotherapy protocols and 10 µg/kg/day s.c. granulocyte colony-
stimulating factor (G-CSF) filgrastim (Neupogen, Roche, Switzerland). Study was 
approved by the local ethics committee, and written informed consent for the PBSC 
collection by LVL and additional testing was obtained from all patients. 
  
2.2. Methods 
2.2.1. PBSC collection 
 PBSCs were collected using a Cobe-Spectra cell separator (MNC program, 
software version 6.0) (Gambro BCT, Lakewood, CO, USA). Venous access was 
established using a dual lumen central venous catheter (Dualise-Cath, Vygon, France), 
placed in subclavian (27 patients), jugular (2 patients) or femoral vein (1 patient). 
 Leukapheresis started when the peripheral blood CD34+ cell count reached 
10x106/L. A minimum of 30x109/L platelets was required before leukapheresis. Patients 
with preapheresis counts of ≥20x106/L CD34+ cells were considered good mobilizers, 
while those with a CD34+ count <20x106/L were considered poor mobilizers. Twelve 
patients were poor mobilizers, and 18 were good mobilizers.  
Bojanic,  5 
 
 The target yield of CD34+ cells was 3.5x106/kg of body weight (BW), except in 
patients with multiple myeloma who were scheduled for double transplantation with 
target yield of 7x106/kg BW.  
 During LVL the total volume of processed blood equaled 6 patients' TBVs, 
calculated by the instrument, based on weight, height and gender. Inlet flow rate was set 
according to instrument calculations. Collection rate was 1.0 ml/min while the collected 
fraction was maintained under manual control at a hematocrit of approximately 1%.  
 A combination of solution citrate dextrose formula A (ACD-A, Baxter, Deerfield, 
IL, USA) and heparin (Heparin, Belupo, Croatia) were used as anticoagulants. The 
addition of 6 IU of heparin per 1 ml of ACD-A allowed us to enhance the ACD-A to 
whole blood ratio to 1:24. Therefore the inlet flow rate was doubled and in the same time 
twice the blood volume was processed. 
 In order to investigate the volume-dependent kinetics of CD34+ cell yield after 
each TBV processed, WBC collection set was modified. Collection bag was replaced 
with a six collection bag set which were connected to the WBC set collection line by 
sterile connection device. Modified set allowed removal of the collected cells every time 
one TBV had been processed and therefore product collected during processing each 
TBV could be analyzed.  
 When the optimal interface for MNC collection was established, the first 
collection bag was opened; bags were changed after processing 1x, 2x, 3x, 4x, 5x and 6x 
the patients' TBV. All aphereses were performed by the same operator and parameters 
were held constant throughout the procedure.  
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 Patients were monitored for adverse reactions and recorded reactions were 
classified according to National Cancer Institute Common Toxicity Criteria (CTC-NCI) 
Classification, Version 2 [4]. In order to prevent symptoms of hypocalcemia all patients 
during LVL received 0.5 g calcium chloride/10 kg BW in 100 ml of saline solution. 
 
2.2.2. Laboratory evaluation of peripheral blood and leukapheresis products 
 Peripheral blood samples taken preapheresis and after processing each TBV, and 
samples from each leukapheresis bag were analyzed for WBC, MNC, platelet and CD34+ 
cell counts. Afterwards, products collected in the first four bags were pooled into one 
bag, while products collected in the fifth and sixth bag were pooled into another bag. 
Samples were taken from each pooled bag and quality of products was compared with 
respect to CD34+ cell count. An intraindividual comparison of the collected CD34+ cells 
was done with respect to their differentiation- (CD38, CD90, HLA-DR) and lineage-
associated markers (CD117, CD33, CD41). Numbers of colony-forming units: 
granulocyte macrophage (CFU-GM), burst forming units-erythroid (BFU-E) and mixed 
units (CFU-MIX) were determined in two pooled bags as well. Finally, products from 
both bags were pooled into one final bag and analysed for WBC, MNC, platelet and 
CD34+ cell count. 
 Cell yields were expressed as both the content of cells in a product and the cell 
yield per kg of patient's BW. Total yield was defined as the sum of the yields of 6 bags. 
Cumulative yield was defined as the sum of the yields collected during processing each 
TBV. CD34+ cell collection efficiency [6, 7] and recruitment factor [8-10] for the various 
cell populations were calculated as previously described. 
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 Complete blood counts on the peripheral blood samples and leukapheresis 
products were obtained on an automated cell counter ADVIA 120 (Bayer, Leverkusen, 
Germany). WBC differential counts were performed manually using Wright-Giemsa-
stained specimens. Mononuclear cells (MNC) were defined as the sum of monocytes and 
lymphocytes.  
 CD34+ cells were analysed by flow cytometry using FACSCalibur (BD 
Biosciences, Heidelberg, Germany) following standard ISHAGE procedure for cell 
staining with anti-CD34-PE (clone 8G12) and anti-CD45-FITC (clone 2D1) monoclonal 
antibodies (BD Biosciences) [11]. CD34+ cell subsets were analyzed using monoclonal 
antibodies to CD38, HLA-DR, CD90, CD117, CD41 and CD33 (BD Biosciences). 
 Short-term culture assay for CFU-GM, BFU-E, CFU-MIX) was performed using 
MethoCult H4433 medium (StemCell Technologies, Vancouver, Canada) [12]. The 
number of colonies was evaluated after 14 days of incubation at 37°C in a humidified 
atmosphere with 5% CO2. 
 Electrolytes calcium, potassium, phosphorus, and magnesium were tested in 
peripheral blood samples obtained pre- and postapheresis using Olympus AU 400 
analyzer (Olympus Diagnostica, Tokyo, Japan).  
2.2.3. Statistical analysis 
 Data were tested for normality using Kolmogorov Smirnov test. All distributions 
were normal, thus means and standard deviations as descriptors and parametric 
procedures were used for all analyses. 
 Repeated measures ANOVA was used to test changes in peripheral blood cells 
during LVL. If repeated measures ANOVA resulted in statistically significant F-ratio, we 
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used paired samples t-tests to test the differences between neighbouring points of 
measurement. In these cases we used Bonferonni's correction for multiple comparisons: 
to preserve the overall p<0.05 level of statistical significance, p<0.008 was considered 
statistically significant when there were 6 comparisons, and p<0.007 when there were 7 
comparisons. Furthermore we used within-between subjects ANOVA to test the possible 
effects of diagnosis (multiple myeloma vs. lymphoma) or level of CD34+ cell 
mobilization (good vs. poor mobilizers) on changes in peripheral blood cells during LVL. 
A 2x2 between subjects ANOVA was used to test the effect of diagnosis and level of 
CD34+ cell mobilization on recruitment factor. Independent samples t-test was used to 
test the differences in CD34+ cell yield between patients with multiple myeloma and 
those with lymphoma, as well as between good and poor mobilizers. We used Spearman's 
rho coefficient to test the association between CD34+ cell total yield with preapheresis 
CD34+ cell count. The influence of processing 6 TBVs as opposed to standard processing 
of 4 TBVs on success of collecting necessary amount of CD34+ cells in patients with 
lymphoma was tested using McNemar's test. Differences in CD34+ cell subpopulations in 
product collected during processing the first 4 TBVs and product collected during 
processing the fifth and sixth TBVs were tested using paired samples t-test. Level of 
statistical significance was set at 0.05 for all analyses and they were performed using 
SPSS 13.0 for Windows (SPSS Inc., Chicago, IL). 
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3. Results 
 Thirty aphereses performed in 30 patients were analyzed. A mean volume of 
26.97±5.48 l (range 17.83-37.29 l) was processed during 305.8±7.6 min (range 290-324 
min) with a mean flow rate of 91.7±18.8 ml/min (60.2-131.9 ml/min). The patients 
received a mean volume of 1120.8±230.1 ml ACD-A (range 740-1510 ml) and 
6725.2±1380.6 U of heparin (range 4440-9060 U). The mean volume of total apheresis 
products was 291.9±13.2 ml (range 255-335ml). After processing 6 TBVs the mean total 
CD34+ cell yield was 4.71±3.79 (range 0.91-16.90) x108/kg BW, and was significantly 
higher in good mobilizers than in poor mobilizers, (6.54±3.93 x106/kg vs. 1.98±0.79 
x106/kg, p<0.001). There were no significant differences in CD34+ yield between the 
myeloma and lymphoma patients.  
 There was a strong correlation between the preapheresis peripheral blood CD34+ 
cell count and the total CD34+ cells yield (ρ=0.860, p<0.001). In both good and poor 
mobilizers, the total CD34+ yield correlated significantly with the preapheresis CD34 
count (ρ=0.83 and ρ=0.89, respectively; p<0.0001). 
 
3.1. Kinetics of peripheral blood cells during LVL 
 The baseline hematological parameters and their changes during apheresis after 
processing each of the 6 TBVs are summarized in table 2. and figure 1. LVL significantly 
decreased the circulating WBC, MNC, and CD34+ cell counts (p<0.001). Post-hoc 
analyses revealed that this effect was due to the significant difference in number of WBC, 
MNC and CD34+ cells between the baseline values and values after processing the first 
TBV (p<0.001). We found no significant interaction between the change in peripheral 
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blood CD34+ cell count and diagnosis (p=0.212) or the level of mobilization of CD34+ 
cells (p=0.62). Platelet count decreased significantly during LVL through each of the 
seven points of measurement (p<0,001).  
 
3.2. Kinetics of PBSC collection 
 PBSCs harvested during processing each TBV volume were collected in a 
separate bag, with mean volume of 48.6±5.1 ml. Yields of cells and CD34+ cell 
collection efficiency during LVL are summarized in table 3. and figure 2. Statistically 
significant change in yield of WBC, MNC, and CD34+ cells during LVL were found 
(p<0.001). Post-hoc analyses revealed that this effect was due to the significantly higher 
yield of all cells while processing the second TBV compared to the first TBV(p<0.001). 
Afterwards the mean yield of WBC, MNC and CD34+ cells remained stable while 
processing the remaining 5 TBVs. No significant interaction between the kinetic of 
CD34+ cell yield and diagnosis (p=0.380) or level of CD34+ cells mobilization were 
found (p=0.886). Although the total amount of harvested CD34+ cells was higher for 
good mobilizers, the kinetics of CD34+ cell collection during different stages of LVL 
were the same for all patients.  
 Cummulative yield of CD34+ cells increased continuously during LVL with each 
processed TBV (p<0.001), which confirmed that the number of CD34+ cells collected 
during apheresis is related to the volume of blood processed.  
 The average total CD34+ cell collection efficiency during LVL was 70.9±33.2%. 
CD34+ cell collection efficiency was lowest during the first TBV processing, but 
afterward remained stable. No significant interaction between the change in CD34+ cell 
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collection efficiency and diagnosis (p=0.309) or the level of CD34+ cell mobilization 
were found (p=0.173).  
 
3.3. Comparison of the total CD34+ cell yield collected during processing 4 TBVs vs. 6 
TBVs  
 Processing 6 TBVs versus 4 TBVs resulted in significantly higher CD34+ cell 
yields; 4.71±3.79x106/kg vs. 3.28±2.89x106/kg, respectively (p<0.001). If leukapheresis 
was stopped after processing 4 TBVs, the target CD34+ cell yield would have been 
achieved after only one procedure in 9 (30%) patients. However, when the procedure was 
prolonged to processing 6 TBVs, the target dose was successfully achieved in 20 (66.7%) 
patients (p=0.001).  
 The results for the group of 20 myeloma patients were analyzed separately 
because their target dose was doubled. With processing 6 TBVs, satisfactory CD34+ 
counts for tandem transplantation was achieved in 6 (30%) patients, for single 
transplantation in 9 (45%) patients, while counts <3.5x106 CD34+/kg were collected in 5 
(25%) patients. If leukapheresis was stopped after processing 4 TBVs, only one patient 
(5%) would have collected enough CD34+ cells for tandem transplantation and 6 (30%) 
for single transplantation  
 
3.4. Quality of products collected during different stages of LVL 
 The intraindividual comparison of quality of cells collected while processing 4 
TBVs and cells collected while processing the fifth and sixth TBVs are presented in table 
4. The CD34+ cell subset analysis revealed no significant difference in the composition 
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of products collected during different stages of LVL. Likewise, the number of CFU-GM, 
BFU-E and CFU-MIX collected from processing 4 TBVs was not significantly different 
from the number of CFUs collected from processing the fifth and sixth TBVs.  
 
3.5. Recruitment of cells during LVL 
 Total number of cells in peripheral blood preapheresis and postapheresis, total 
number of cells in the leukapheresis products, and recruitment factor for WBC, MNC, 
granulocytes, CD34+ cells and platelets are presented in table 5. The recruitment factor 
was calculated for each of these cells in order to find out whether cell-specific 
recruitment occurred during LVL. The highest recruitment factor (3.2±1.6) was found for 
CD34+ cells. Statistically significant difference in CD34+ cell recruitment factor was 
found between good (2.8±0.4) and poor mobilizers (4.1±0.5), respectively (p=0.044).  
There was no difference in recruitment factors concerning patients' diagnoses (p=0.112). 
 
3.6. Side effects and electrolyte changes during LVL 
 All LVLs were well tolerated, and none of procedures had to be discontinued. 
Apheresis related adverse reactions were restricted to mild symptoms of citrate toxicity. 
Only one patient experienced mild perioral paresthesias, classified as grade 1. Although 
significant decreases in platelet count were observed after LVL, no bleeding episodes 
occurred, and there was no need for transfusion support. 
 All analysed electrolytes decreased significantly with respect to the basal values: 
calcium 5.18±4.10%, (p=0.005), potassium 11.75±7.46% (p<0.001), magnesium 
11.98±5.44% (p<0.001), and phosphorus 17.22±16.06% (p=0.024). Although calcium 
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concentration decreased significantly with respect to basal values, it still remained within 
referent values (2.38±0.40 mmol/L vs. 2.24±0.22mmol/L) [13]. Other analysed 
electrolytes decreased markedly below referent interval: potassium 3.92±0.35 mmol/L vs. 
3.47±0.38 mmol/L, magnesium 0.71±0.08 vs. 0.65±0.09, and phosphorus 0.87±0.28 
mmol/L vs. 0.73±0.2 mmol/L [13]. Nevertheless, none of our patients experienced 
clinically relevant side effects related to changes in these electrolytes. 
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4. Discussion 
 Leukapheresis has been successfully used in PBSC collection for over 20 years, 
however several topics still remain unresolved regarding the optimal method of collection 
and the volume of processed blood. Processing of larger blood volumes in single LVL 
may improve CD34+ cell yield, consequently reducing the number of required 
procedures and diminishing the total cost of collections [2, 4]. Another rationale for use 
of LVL is the narrow peak of the CD34+ cells in the peripheral blood, present only for a 
short period after mobilization, and therefore the optimal time for successful collection 
would not likely be missed [14]. 
 Results of previous studies which compared standard vs. LVL processing varied 
considerably [2, 4, 10, 14-18]. It is difficult to establish a control group with comparable 
patients due to high interindividual variability regarding patients' characteristics, such as 
age, gender, TBV, stage of disease, previous treatment, and baseline blood count values. 
Even if the same patient is analyzed the following day, peripheral blood CD34+ cell 
count could halve or double overnight. The optimal study design would be to compare 
products collected during the same procedure at different time, which was done in this 
study, and differences caused by interindividual variability were excluded. Studies of 
kinetics of PBSC enrichment during LVL showed variable results [3, 8-10, 19-31], which 
could be consequence of difference in volumes of processed blood. Therefore, processed 
blood volume in our study was standardized and strictly related to the patient's TBV. 
Processing 6 TBVs was accomplished by doubling inlet flow rate and additional use of 
heparin, along with prolongation of procedure to 5 hours. Duration of LVL could have 
been prolonged even more, but was limited to 5 hours because of patients’ comfort and 
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tolerance, and consistence with working hours of apheresis unit, quality control and cell 
processing laboratories. Time-consuming LVL raises an issue of patient’s compliance, 
but previous studies showed that cooperation for prolonged apheresis procedure could be 
achieved even in pediatric patients [17, 25, 26]. 
Strong correlation between the preapheresis CD34+ cell count and the total 
CD34+ cell yield was found, both in good and poor mobilizers. Accordingly to our 
results as well as other reports [5, 22, 27, 29], even in LVL setting, the preapheresis 
CD34+ cell count is still the best predictor of the outcome of PBSC collection, although 
the volume of blood processed during LVL also affects the total yield. 
 LVL is feasible only if the level of CD34+ cells in the blood is maintained 
throughout the procedure. Although a decline in CD34+ cell level was documented in all 
patients, our study showed that even after processing 6 TBVs there was no exhaustion of 
the peripheral blood CD34+ cells. Kinetic study showed that decrease in CD34+ count is 
related to the number of the TBVs processed. The drop in CD34+ cell count was most 
evident at the beginning of leukapheresis, as cells were packed into the apheresis device 
set [3, 26]. At the same time, separator draws patient's blood while returns saline which 
filled set lines, which can cause hemodilution and contribute to CD34+ cell decrease.  
 Our results confirm that CD34+ cells were collected at a steady rate throughout 
the LVL [9, 19, 26, 30]. The lowest CD34+ cell yield and collection efficiency were 
observed at the very beginning of LVL, which can be explained by the time required to 
establish interface, and by a dilution effect in the first collection bag, caused by the 
automated filling with saline [19, 29, 31]. In the remaining collection period, the CD34+ 
cell yield and collection efficiency were stable, without any time-dependent changes, as 
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observed by others [9, 10].  Furthermore, the MNC purity remained constant during LVL, 
confirming that enhanced blood volume processing doesn’t affect the product quality in 
terms of higher granulocyte contamination during the final stages of apheresis [19]. It is 
important to emphasize that in spite of decrease of peripheral blood CD34+ cell count 
during LVL, the total cumulative CD34+ cell yield increased steadily after each blood 
volume processed. Kinetics of CD34+ cell collection were similar and stable regardless 
of diagnosis or level of CD34+ cell mobilization, therefore all patients could have benefit 
from LVL [32].  
 Use of modified sets enabled us to compare how many cells would be collected 
after processing standard 4 TBVs vs. 6 TBVs. CD34+ cell yield was higher when 
leukapheresis was extended, which could be particularly beneficial in poor mobilizers. 
Our results confirmed that likelihood for collecting target number of CD34+ cells was 
greater with use of LVL than with standard leukapheresis [4, 28].  
 Current protocols for myeloma patients require tandem transplantation [33, 34], 
and it is common practice to collect sufficient cells for two grafts. That is sometimes 
challenging in heavily pretreated patients, particularly those who previously received 
lenalidomide [4, 35]. Moreover, some data demonstrated different mobilization of PBSCs 
and myeloma cells, with peak levels of myeloma cells occurring few days after CD34+ 
cells [36-38]. Since LVL allows collection of more CD34+ cells, fewer days are required 
to obtain target cell dose, and use of LVL could result in lower tumor contamination of 
graft [36-38]. Zubair et al. [33] estimated that using LVL in myeloma patients, the cost 
savings could be greater than $7,597 per patient.  
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 Leukapheresis product consists of hematopoietic stem and progenitor cells in 
different stages of differentiation [39-41]. Previous studies, [39, 41, 42] as well as ours, 
reported that the majority of collected CD34+ cell coexpressed CD38, HLA-DR or CD33 
associated with commitment to different hematopoietic lineages. Our study first analysed 
CD34+ cell subpopulations in product collected while processing as many as 6 TBVs, 
and showed no difference in the composition of products collected during different stage 
of LVL. This finding argues against a preferential release of particular CD34+ cell 
subsets during the LVL [27]. Our data confirm that LVL results in a higher CD34+ cell 
yield without change in graft quality.  
 Higher CD34+ cell yield harvested by processing a larger volume of blood was 
explained with a steady recruitment of PBSCs during leukapheresis [8, 9, 18, 19]. In our 
study, threefold more CD34+ cells were collected than were present in blood before 
leukapheresis. The recruitment was limited to MNC and CD34+ cells, which were 
predominantly removed during the procedure, which was also observed by other authors 
[8, 23, 24, 43]. Interestingly, recruitment factor for CD34+ cells in our study was 
significantly higher in poor mobilizers than in good mobilizers, which points to the 
importance of LVL in patients who mobilize low number of CD34+ cells  [17]. The 
underlying mechanisms of PBSCs recruitment during LVL are not clear, and few 
hypotheses have been proposed. Some authors explained recruitment of PBSCs merely 
by the stimulating effect of G-CSF administration [44], while others suggested that it was 
mediated by a negative feedback mechanism caused by the decline of the peripheral 
blood CD34+ cell count during LVL [8, 10]. Another possible mechanism is modification 
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of PBSCs homing and transmigration caused by changes in their microenvironment, 
induced by use of heparin [15, 45, 46] and citrate-induced hypocalcemia [27, 47].  
 Results of our study are in favour of LVL but some drawbacks should also be 
mentioned. LVL is definitely time-consuming because processing 6 TBVs requires 5 
hours. Implementation of LVL has implications on working hours of apheresis 
department as well as quality control and cell processing laboratory. Timely completion 
of LVL requires high blood flow rates. In some studies it wasn't possible to establish the 
required inlet flow rate, and the procedures were shortened because of catheter related 
problems [10, 18]. We didn't observe any problem related to high inlet flow rate, but all 
our patients had apheresis catheter which we recommend for LVL. LVL may result in an 
excess of collected CD34+ cells, therefore it shouldn’t be used in patients who mobilized 
high number of CD34+ cells. 
 A limiting factor for widespread use of LVL may be patients’ tolerance of the 
procedure [2, 3]. Larger volumes of infused anticoagulants causes electrolyte imbalance 
such as hypocalcemia, metabolic alkalosis, hypokalemia and hypomagnesemia [48]. In 
agreement with previous reports [33, 48], we did not observe increase in number of 
adverse events during LVL collection. Buchta et al. [49] showed that prophylactic 
calcium infusion during LVL reduced the incidence of citrate-related symptoms without 
affecting the technical performance or the number of CD34+ cells collected, as was 
confirmed by our results. Our study also confirmed marked platelet decrease after 
processing each TBV with halved platelet count after LVL [3, 48]. The additional heparin 
administration enables the reduction of infused volume of citrate anticoagulant, but might 
represent an additional risk factor for bleeding complications in thrombocytopenic 
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patients with central venous catheters [50]. Heparin-induced thrombocytopenia (HIT) and 
associated thrombotic complications could develop in a newly exposed patient, or rapid-
onset complications might occur in a patient with a recent prior history o HIT [51]. 
Processing up to 6 TBVs according to our results could be performed safely because no 
severe adverse reactions occurred, including bleeding complications. Although it lasts 
longer,  patients will probably tolerate an extra hour of collection easier than another 
procedure on consecutive days which would increase the total cost of treatment and 
expose them to risks of central venous line complications and additional leukaphereses 
[24].  
 LVL could be strongly recommend for patients who mobilized low number of 
CD34+ cells, and patients who need high dose of CD34+ cells, including double 
transplantation or in vitro processing of leukapheresis product where a significant loss of 
cells is expected. If role of LVL is considered in setting of new mobilizing agents, such 
as plerixafor used in case of previously unsuccessful mobilization [52, 53], there is no 
doubt that LVL should be performed to collect maximum PBSCs in one procedure. From 
the data presented, we conclude that processing of 6 TBVs during LVL is efficient and 
safe technique, which significantly reduces the number of aphereses needed to obtain 
target number of CD34+ cells. Whether or not further increase of the processed blood 
volume could improve the quality of graft must be evaluated in forthcoming studies. 
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Tables 
 
 
Table 1. Patients' characteristics 
Gender (male / female) 16 / 14 
Age (years)* 50.1±10.9 (19-61) 
Body weight (kg)* 78.3±15.4 (57–108) 
Total blood volume (ml)* 4618.6±140.5 (3463–6761) 
Diagnosis (N)  
Multiple myeloma 20 
Non-Hodgkin's lymphoma  8 
Hodgkin's disease  2 
Mobilization (N)  
cyclophosphamide (4 g/m2)  20 
HDIM  7 
ICE  1 
mini BEAM 1 
DHAP 1 
*mean±SD (range); HDIM=high-dose ifosfamide, mitoxantrone; ICE=ifosfamide, 
carboplatin, etoposide; mini BEAM=carmustine, etoposide, cytarabine, melphalan; 
DHAP=dexamethasone, cytarabine, cisplatin  
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Table 2. Kinetics of WBC, MNC, CD34+ cells and platelets in the peripheral blood during LVL 
(mean ± SD). Levels of statistical significance were calculated comparing the results after each 
processed total blood volume (TBV) with the following 
 Peripheral blood cells  
Processed 
TBV  
WBC x 
109/L 
WBC 
decrease 
from 
baseline % 
MNC 
x109/L 
MNC 
decrease 
from 
baseline % 
CD34+ 
x106/L 
CD34+ 
cell 
decrease 
from 
baseline
% 
Platelet 
x 109/L 
Platelets 
decrease 
from 
baseline 
%  
Baseline 
14.39 
±7.68 
100 
2.02± 
0.81 
100 
48.35 
±44.80 
100 
99.75 
±40.17 
100 
p* <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
1x 
12.10 
±6.91 
83.20 
 ± 10.74 
1.38 
±0.57 
69.27  
± 12.69 
27.86 
±23.19 
63.46  
±20.38 
79.06 
±33.55 
79.26 
±9.06 
p* NS NS p=0.004 NS NS NS <0.001 <0.001 
2x 
11.83 
±6.69 
82.48 
 ± 12.64 
1.26 
±0.51 
64.23  
± 14.71 
26.71 
±25.29 
58.17 
±18.01 
71.75 
±32.69 
72.24 
±12.73 
p* NS NS 0.005 0.007 NS NS <0.001 <0.001 
3x 
11.64 
±6.57 
80.07 
 ± 10.20 
1.15 
±0.41 
58.58  
± 10.37 
23.42 
±23.00 
51.20 
±17.02 
63.41 
±25.46 
64.55 
±11.23 
p* NS NS 0.006 0.003 NS NS <0.001 <0.001 
4x 
11.41 
±6.59 
78.01 
 ± 12.39 
1.05 
±0.38 
53.98  
± 11.91 
21.02 
±19.73 
47.72 
±21.27 
58.75 
±25.41 
59.88 
±13.61 
p* NS NS NS NS NS NS <0.001 <0.001 
5x 
11.16 
±6.47 
76.67 
 ± 14.50 
1.01 
±0.35 
52.54  
± 13.01 
19.63 
±16.13 
46.47  
±19.08 
55.20 
±25.14 
56.65 
±16.21 
p* NS NS NS NS NS NS <0.001 <0.001 
6x 
11.09 
±6.53 
76.01 
 ± 14.56 
12.14 
±8.46 
50.35  
± 16.21 
17.61 
±14.05 
45.95  
±18.64 
49.44 
±21.46 
51.65 
±15.89 
F6,156 19.168 46.828 42.029 138.430 15.368 61.054 62.312 130.902 
p** <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
p* paired samples t-tests; p** repeated measures ANOVA 
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 Table 3. Yields of WBC, MNC and CD34+ cells collected in separate bags and CD34+ cell 
collection efficiencies (CE) during each total blood volume processed (mean±SD). Levels of 
statistical significance were calculated comparing the results after each processed total blood 
volume (TBV) with the following 
 Yield 
Processed 
TBV 
WBC 
x10
9
/L 
WBC 
x10
8
/kg  
MNC 
x10
9
/L 
MNC 
x10
8
/kg 
CD34+  
x10
6
/L 
CD34+ 
x10
6
/kg 
CD34+ cell 
CE (%) 
1x 
149.7 
±61.4 
0.87 
±0.43 
80.3 
±39.5 
0.45 
±0.23 
12.6 
±10.7 
0.71 
±0.61 
40.6 
±18.7 
p* NS p<0.001 p<0.001 p<0.001 NS p=0.004 p<0.001 
2x 
162.1 
±57.8 
1.02 
±0.41 
88.4 
±36.6 
0.56 
±0.22 
14.3 
±14.2 
0.87 
±0.73 
68.6 
±25.3 
p* NS NS NS NS NS NS NS 
3x 
150.9 
±68.3 
0.97 
±0.36 
82.2 
±33.5 
0.53 
±0.19 
14.5 
±16.2 
0.87 
±0.84 
74.4 
±32.6 
p* NS  NS NS NS NS NS NS 
4x 
152.6 
±48.6 
0.96 
±0.32 
80.5 
±29.8 
0.50 
±0.19 
13.4 
±14.1 
0.82 
±0.82 
73.8 
±29.2 
p* NS NS NS NS NS NS NS 
5x 
156.7 
±46.3 
0.98 
±0.28 
81.6 
±32.1 
0.48 
±0.18 
13.6 
±10.1 
0.80 
±0.60 
74.4 
±24.2 
p* NS NS NS NS NS NS NS 
6 
159.1 
±46.0 
1.01 
±0.34 
79.6 
±27.5 
0.49 
±0.19 
12.9 
±9.1 
0.82 
±0.51 
79.5 
±28.3 
F5,125 1.489 3.187 3.979 4.808 0.242 3.082 9.927 
p** 0.198 0.041 0.002 <0.001 0.943 0.012 <0.001 
Total 
product 
149.7 
±61.4 
5.71 
±1.97 
80.3 
±39.5 
3.32 
±3.86 
126.2 
±107.2 
4.71 
±3.79 
70.9 
±33.2 
p* paired samples t-test; p** repeated measures ANOVA 
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Table 4. Comparison of quality of leukapheresis products collected during different stage of LVL: 
subset analysis of CD34+ cells and numbers of CFU-GM, BFU-E and CFU-MIX colonies /105 
cells after short-term culture 
Subsets of CD34+ cells 
TBV processed  
1.-4. TBV 
TBV processed 5th 
and 6th times 
p* 
CD38+ (% CD34+ cells) 98.90±2.33 99.07±1.67 0.669 
CD34+CD38+ (x108/L) 12.74±10.47 12.13±11.09 0.238 
HLA-DR+ (% CD34+cells) 98.67±1.84 99.02±1.30 0.100 
CD34+HLA-DR+ (x108/L) 11.90±10.29 11.30±10.45 0.147 
CD90+ (% CD34+ cells) 46.69±19.77 47.72±20.82 0.320 
CD34+CD90+ (x108/L) 6.80±6.7 6.76±6.3 0.884 
CD117+ (% CD34+ cells) 94.15±4.75 94.48±4.64 0.529 
CD34+CD117+ (x108/L) 11.39±9.12 11.12±9.19 0.349 
CD41+ (% CD34+ cells) 21.97±19.28 19.74±20.09 0.080 
CD34+CD41+ (x108/L) 2.34±2.20 2.21±2.16 0.508 
CD33+ (% CD34+ cells) 89.10±13.49 89.52±12.33 0.416 
CD34+CD33+ (x108/L) 10.91±8.44 10.68±8.55 0.483 
Number of colonies /10
5
 cells    
CFU-GM 77.63±31.88 73.65±24.27 0.344 
BFU-E 47.19±27.72 48.94±25.23 0.558 
CFU-MIX 16.28±7.57 15±5.31 0.301 
p* paired samples t-tests 
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Table 5. Preapheresis and postapheresis total number of cells in peripheral blood, total number of 
collected cells in the leukapheresis products and recruitment factor 
Parameters Preapheresis Postapheresis 
Total number of 
harvested cells 
Recruitment 
factor* 
WBC (x108) 676.70±416.73 527.36±368.78 439.69±156.81 1.64±0.54 
MNC (x108) 96.32±45.07 46.56±20.49 205.47±103.26 2.72±0.69 
Granulocyte 
(x108) 
580.37±385.53 480.79±355.94 234.21±137.95 1.42±0.51 
CD34+ cells 
(x106) 
226.80±204.88 83.37±68.77 540.12±562.95 3.23±1.61 
Platelets 
(x109) 
469.47±210.93 227.70±87.77 313.72±183.12 1.17±0.20 
 
*Recruitment factor = absolute number of cells in blood postapheresis + absolute number of 
cells collected/ absolute number of cells in blood preapheresis 
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Figures 
 
Figure 1. Decrease of WBC, MNC, CD34+ cells and platelets during LVL expressed as a mean 
percentage from baseline values  
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Figure 2. Yields of WBC, MNC and CD34+ cells / kg BW collected after each blood volume 
processed during large volume leukapheresis expressed as a mean 
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